A numerical perspective on Nature authors.

For Hans-Henrik Kristensen, working at Danish biotech company Novozymes offers him the benefits of both academic and industrial research. He rarely finds funding a limiting factor and has plenty of freedom in the early, innovative stages of a project. Of course, once his team identifies a potential drug, priorities shift — business goals are established, deadlines appear and firm project plans must be implemented. Luckily, there is plenty of scope for collaboration — both with internal departments, for specific aspects of a project such as DNA sequencing, and externally with groups that share research interests. Kristensen's latest work describes a new natural antibiotic that has both the potential for commercial production and, more importantly, real therapeutic promise (see page 975).

13 papers published in Nature so far this year have contributing authors working in Denmark (total number of papers published=672).

63 contributing authors on 2005 Nature papers work in Denmark (total number of contributing authors=4,585).

194 papers published in Nature this year have contributing authors working in industry.

20 authors working in industry report original research in Nature this week.